DARSHANKUMAR A DAVE

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology CHARLESTON, WV NPI 1033155437

General Payments — all program years on this page

$2,299.36

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 82
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $702.81 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $536.0917
Education $166.723

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABBVIE INC. $220.5211
Alexion Pharmaceuticals, Inc. $150.002
Lilly USA, LLC $117.701
Acerta Pharma LLC $110.621
ARGENX US, INC. $53.542
PFIZER INC. $33.712
CATALYST PHARMACEUTICALS, INC. $16.721

By program year

Program yearAmountRecords
2018 $155.935
2019 $455.539
2021 $208.5318
2022 $409.2022
2023 $367.368
2024 $702.8120

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1093885819 Alexion Pharmaceuticals, Inc. $100.00 05/02/2024 Education Undisputed 01/23/2026 View at CMS
1094026229 Alexion Pharmaceuticals, Inc. $50.00 05/02/2024 Education Undisputed 01/23/2026 View at CMS
1103604796 ABBVIE INC. $6.59 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604798 ABBVIE INC. $122.95 01/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604800 ABBVIE INC. $7.20 02/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604802 ABBVIE INC. $7.80 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604804 ABBVIE INC. $16.58 03/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604806 ABBVIE INC. $5.84 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604808 ABBVIE INC. $8.66 05/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604810 ABBVIE INC. $8.05 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604812 ABBVIE INC. $19.82 07/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604814 ABBVIE INC. $8.53 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103604816 ABBVIE INC. $8.50 07/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105901214 AstraZeneca Pharmaceuticals LP $110.62 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131608437 PFIZER INC. $17.18 08/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131608441 PFIZER INC. $16.53 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136125343 Lilly USA, LLC $117.70 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142110473 ARGENX US, INC. $33.24 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142120169 ARGENX US, INC. $20.30 11/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144447918 CATALYST PHARMACEUTICALS, INC. $16.72 10/08/2024 Education Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.